Please note that the posts on The Blogs are contributed by third parties. The opinions, facts and any media content in them are presented solely by the authors, and neither The Times of Israel nor its partners assume any responsibility for them. Please contact us in case of abuse. In case of abuse,
Image: Unsplash
Whether open innovation and venture capital activities should be executed in close cooperation or separately largely depends on the organization. For more mature, innovative companies, separating CVC and open innovation may make these functions quicker and more effective. For those organizations that are early in their innovation and digital transformation journey, keeping them close may be a better idea. This is because both functions are trying to still figure out how similar or different their scope is and what are the best tools and geographies to work with. Working on these questions jointly may save a lot of time, effort, money, but also create a better structu
Global Bioengineered Skin Substitutes Market to Reach $4.33 Billion by 2030
The bioengineered skin substitutes market is currently at a blooming phase, with the presence of various juggernauts such as AbbVie, Inc., Integra LifeSciences Corporation, Smith & Nephew plc, and Stryker Corporation, and other medium and small-medium enterprises that are offering a wide range of bioengineered skin substitutes products in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.
Technological advancements in wound biologics coupled with innovations in the field of tissue engineering have led to the development of advanced wound healing options and strategies, including bioengineered skin substitutes. These products are being designed to treat a wide range of acute and chronic wounds that pose a serious healthcare threat g